We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02570490
Recruitment Status : Completed
First Posted : October 7, 2015
Last Update Posted : April 19, 2019
Sponsor:
Information provided by (Responsible Party):
Arrevus Inc.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Phase 3, randomized, double-blind, multi-center efficacy and safety study to evaluate an oral CEM-102 loading dose regimen compared to oral linezolid in the treatment of subjects with ABSSSI

Condition or disease Intervention/treatment Phase
Acute Bacterial Skin and Skin Structure Infections Drug: sodium fusidate Drug: linezolid Phase 3

Detailed Description:
The primary objective is to demonstrate the non-inferiority of oral CEM-102 (loading dose regimen of 1500 mg every 12 hours for 2 doses, followed by 600 mg every 12 hours thereafter) compared to oral linezolid (600 mg every 12 hours), each administered for 10 days, for Early Clinical Response (ECR) in the intent to treat (ITT) analysis set in subjects with acute bacterial skin and skin structure infections (ABSSSI). Subjects with an ABSSSI caused by suspected or documented Gram-positive pathogen(s) at baseline will be randomized 1:1 to study treatment
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 716 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of Oral Sodium Fusidate (CEM-102) Compared to Oral Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infections
Study Start Date : November 2015
Actual Primary Completion Date : November 2016
Actual Study Completion Date : November 2016

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: CEM-102 (Sodium fusidate)
1500 mg by mouth every 12 hours for 2 doses, then 600 mg by mouth every 12 hours thereafter, until end of therapy (10 days total)
 Drug: sodium fusidate
Other Name: CEM-102
Active Comparator: Linezolid
600 mg by mouth every 12 hours for 10 days
 Drug: linezolid


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Proportion of subjects with a response for Early Clinical Response [ Time Frame: 48 to 72 hours after starting treatment ]
    Proportion of subjects with a response for Early Clinical Response (ECR), defined as alive and achieved ≥ 20% reduction from baseline in the lesion size at 48-72 hours after start of study drug, without receipt of additional non-study antibiotic therapy.


Secondary Outcome Measures :
  1. Proportion of subjects with clinical success at Post-treatment Evaluation [ Time Frame: 7 to 14 days after end of treatment ]
    Proportion of subjects with clinical success at PTE, in the ITT and clinically evaluable (CE) analysis sets.

  2. Incidence of adverse events [Safety and tolerability], Clinical Laboratory Evaluations [ Time Frame: Up to 24 months ]
    Incidence of adverse events, vital sign changes, physical exam changes, and clinical laboratory evaluations will be presented by study arm


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adolescents between 12 to 18 years old must weigh >60 kg
  • Patients diagnosed with ABSSSI with at least one systemic sign of infection
  • Diagnosed with cellulitis, major cutaneous abscess, or wound infections (traumatic or surgical)
  • Surface redness, edema or induration must be of a minimum surface area of 75 cm2, or extending ≥5 cm from the peripheral margin of the abscess
  • Suspected or documented ABSSSI caused by a Gram-positive pathogen

Exclusion Criteria:

  • Involving a chronic diabetic foot infection (diabetic foot ulcer)
  • Involving burns
  • Involving an anatomical location (e.g. perirectal area) where the incidence of Gram-negative and/or anaerobic pathogen involvement is likely
  • Documented bacteremia associated with the current ABSSSI
  • Known severe renal impairment, as indicated by estimated CrCl <30 mL/min (by Cockcroft-Gault calculation)
  • Evidence of significant liver disease: ALT >3x ULN, or direct bilirubin >ULN; known cirrhosis with decompensation (i.e. Child-Pugh Class B or C disease)
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02570490


Locations
Show Show 62 study locations
Sponsors and Collaborators
Arrevus Inc.
Investigators
Layout table for investigator information
Study Director: Richard Pushkin, MD Melinta Therapeutics, Inc.
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Arrevus Inc.
ClinicalTrials.gov Identifier: NCT02570490    
Other Study ID Numbers: CE06-301
First Posted: October 7, 2015    Key Record Dates
Last Update Posted: April 19, 2019
Last Verified: June 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Arrevus Inc.:
fusidic acid
skin infection
Additional relevant MeSH terms:
Layout table for MeSH terms
Infections
Communicable Diseases
Skin Diseases, Bacterial
Disease Attributes
Pathologic Processes
Bacterial Infections
Bacterial Infections and Mycoses
Skin Diseases, Infectious
 Skin Diseases
Linezolid
Fusidic Acid
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action